Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis
CY Yang, CS Chang-Chien, YF Liaw - Pancreas, 1987 - journals.lww.com
CY Yang, CS Chang-Chien, YF Liaw
Pancreas, 1987•journals.lww.comA controlled trial with synthetic protease inhibitor gabexelate mesilate (FOY) in the treatment
of acute pancreatitis was conducted in a total of 42 patients. The age, sex, etiology of
pancreatitis, initial serum amylase level, and amylase creatinine clearance ratio were
comparable between FOY-treated and control groups. FOY did not alter the course of the
disease, but there was a weak trend toward lower morbidity and mortality in the FOY-treated
patients. These results may justify further, larger scale studies or evaluation of alternate …
of acute pancreatitis was conducted in a total of 42 patients. The age, sex, etiology of
pancreatitis, initial serum amylase level, and amylase creatinine clearance ratio were
comparable between FOY-treated and control groups. FOY did not alter the course of the
disease, but there was a weak trend toward lower morbidity and mortality in the FOY-treated
patients. These results may justify further, larger scale studies or evaluation of alternate …
Abstract
A controlled trial with synthetic protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis was conducted in a total of 42 patients. The age, sex, etiology of pancreatitis, initial serum amylase level, and amylase creatinine clearance ratio were comparable between FOY-treated and control groups. FOY did not alter the course of the disease, but there was a weak trend toward lower morbidity and mortality in the FOY-treated patients. These results may justify further, larger scale studies or evaluation of alternate dosage or route of administration.
Lippincott Williams & Wilkins